

**S4 Table.** Cox proportional hazard analysis and logistic regression analysis for predicting PFS and response to weekly paclitaxel

	Cox proportional hazard analysis on association with PFS of weekly paclitaxel (univariate)		Logistic regression analysis on association with response to weekly paclitaxel	
	HR (95% CI)	p-value	OR (95% CI)	p-value
Age	1.00 (0.98-1.02)	0.768	1.02 (0.97-1.09)	0.453
Sex				
Male	Reference		Reference	
Female	1.13 (0.63-2.03)	0.687	0.49 (0.10-1.86)	0.329
ECOG PS				
0, 1	Reference		Reference	
2, 3	4.65 (1.99-10.87)	< 0.001	0.50 (0.03-3.32)	0.538
Primary cutaneous angiosarcoma				
Yes	Reference		Reference	
No	1.00 (0.54-1.86)	0.997	0.43 (0.12-1.56)	0.190
Primary site: liver				
No	Reference		Reference	
Yes	1.92 (0.98-3.73)	0.056	0.15 (0.01-0.89)	0.085
Primary site: lung				
No	Reference		Reference	
Yes	0.69 (0.25-1.94)	0.481	3.58 (0.40-32.53)	0.225
Primary site: heart				
No	Reference		Reference	
Yes	1.47 (0.52-4.16)	0.473	1.08 (0.05-9.26)	0.951
Presence of liver involvement				
No	Reference		Reference	
Yes	1.99 (1.09-3.65)	0.025	0.31 (0.06-1.16)	0.104
Presence of lung involvement				
No	Reference		Reference	
Yes	1.18 (0.63-2.19)	0.604	2.22 (0.57-8.25)	0.234
Presence of bone involvement				
No	Reference		Reference	
Yes	1.15 (0.64-2.04)	0.648	1.01 (0.27-3.45)	0.991
Presence of lymph node involvement				
No	Reference		Reference	
Yes	0.75 (0.41-1.37)	0.356	2.75 (0.79-9.73)	0.109
FNCLCC grade				
1	Reference		Reference	
2	2.00 (0.59-6.77)	0.267	0.00 (0.00-NA)	0.994
3	2.43 (0.65-9.10)	0.188	0.00 (0.00-NA)	0.994
Previous operation intent				
None	Reference		Reference	
Curative	0.52 (0.26-1.05)	0.066	1.22 (0.27-5.16)	0.786
Palliative	0.68 (0.34-1.36)	0.275	1.33 (0.29-5.70)	0.699
Pre-chemotherapy bilirubin	1.22 (1.03-1.44)	0.023	0.71 (0.22-1.21)	0.404
Pre-chemotherapy albumin	0.43 (0.29-0.66)	< 0.001	2.37 (0.88-7.66)	0.111

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; PFS, progression-free survival; FNCLCC, Federation Nationale des Centres de Lutte Contre Le Cancer; NA, not available.